Literature DB >> 7260853

A comparison of noninvasive imaging modalities in the melanoma patient.

M J Doiron, M E Bernardino.   

Abstract

The results of radionuclide (RN) liver scans, computed tomography (CT), and ultrasonography (US) were compared in 163 patients. Thirty-eight patients had all three studies, while ten were examined by CT and RN liver scans. One hundred fifteen patients had only US and RN studies. Radionuclide liver scanning demonstrated more false positive and negative studies than CT or US. Also, CT and US demonstrated more areas of metastasis during a single examination than RN liver scans. Ultrasonography displayed roughly the same accuracy of CT when a technically adequate examination was obtained. However, US was hampered by technically inadequate studies in 19% of 153 patients because of interfering intestinal gas. Computed tomography proved the most accurate and reliable modality in 48 patients.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7260853     DOI: 10.1002/1097-0142(19810601)47:11<2581::aid-cncr2820471112>3.0.co;2-8

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  3 in total

1.  Melanoma metastases in the abdomen and pelvis: Frequency and patterns of spread.

Authors:  Andrew T Trout; Risa S Rabinowitz; Joel F Platt; Khaled M Elsayes
Journal:  World J Radiol       Date:  2013-02-28

2.  Ultrasound, CT, MRI, or PET-CT for staging and re-staging of adults with cutaneous melanoma.

Authors:  Jacqueline Dinnes; Lavinia Ferrante di Ruffano; Yemisi Takwoingi; Seau Tak Cheung; Paul Nathan; Rubeta N Matin; Naomi Chuchu; Sue Ann Chan; Alana Durack; Susan E Bayliss; Abha Gulati; Lopa Patel; Clare Davenport; Kathie Godfrey; Manil Subesinghe; Zoe Traill; Jonathan J Deeks; Hywel C Williams
Journal:  Cochrane Database Syst Rev       Date:  2019-07-01

3.  Multimodality detection of metastatic melanoma.

Authors:  A K Kuan; F I Jackson; J Hanson
Journal:  J R Soc Med       Date:  1988-10       Impact factor: 18.000

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.